Group 1 - Company Jiukang Bio (SZ 300406) announced on October 31 that it has received three patent certificates from the National Intellectual Property Administration of the People's Republic of China, including "A Digoxin Detection Kit" and "Fully Automatic Coagulation Analyzer" [1] - For the year 2024, Jiukang Bio's revenue composition is 100% from the healthcare sector [1] - As of the report date, Jiukang Bio has a market capitalization of 8 billion yuan [1]

Core Viewpoint - Shenzhen New Industry Biomedical Engineering Co., Ltd. has received a medical device registration certificate for its "Fully Automatic Coagulation Analyzer" from the Guangdong Provincial Drug Administration [2] Group 1: Company Developments - The company announced the receipt of a medical device registration certificate on August 15 [2] - The product "Fully Automatic Coagulation Analyzer" is a significant addition to the company's portfolio [2] Group 2: Financial Overview - For the year 2024, the company's revenue composition is projected to be 99.82% from in vitro diagnostics and 0.18% from other businesses [2]